OBJECTIVE: Deep vein thrombosis (VT) can result in vein wall injury, which clinically manifests as post-thrombotic syndrome. Postinjury fibrosis may be modulated in part through cellular cysteine-cysteine receptor 7 (CCR7)-mediated events. We tested the hypothesis that late vein wall fibrotic remodeling is dependent on CCR7. APPROACH AND RESULTS: CCR7(-/-) and C57BL/6 wild-type mice had inferior vena cava VT induced by nonstasis or stasis mechanisms. In both models, VT size was largest at day 1 and trended down by day 21, and CCR7(+) cells peaked at day 8 in wild-type mice. No significant differences in VT resolution were found in CCR7(-/-) as compared with wild type in either model. In the nonstasis VT model, vein wall changes consistent with fibrotic injury were evidenced by significant increases in collagen I, III, matrix metalloproteinase 2, and transforming growth factor-β gene expression, increases in α-smooth muscle actin and fibroblast specific protein-1 antigen, and total collagen at 8 days. Correspondingly, SM22α and fibroblast specific protein-1, but not DDR2(+) cells, were increased at 8 days. Early wild-type thrombus exposure inhibited profibrotic gene expression in CCR7(-/-) in ex vivo vein wall culture. Bone marrow chimera experiments further showed that circulating CCR7(+) leukocytes partially rescued midterm profibrotic changes in CCR7(-/-) mice. In human histological sections of chronic thrombosed femoral veins, CCR7(+) cells were present in the fibrotic areas. CONCLUSIONS: Post-thrombotic vein wall remodeling is impaired in CCR7(-/-) mice, with a profibrotic phenotype, is dependent on the thrombotic mechanism, and is mediated by circulating CCR7(+) cells. Unlike other postinjury fibrotic responses, CCR7(+) signaling may be important for positive vein wall remodeling after VT.
OBJECTIVE:Deep vein thrombosis (VT) can result in vein wall injury, which clinically manifests as post-thrombotic syndrome. Postinjury fibrosis may be modulated in part through cellular cysteine-cysteine receptor 7 (CCR7)-mediated events. We tested the hypothesis that late vein wall fibrotic remodeling is dependent on CCR7. APPROACH AND RESULTS:CCR7(-/-) and C57BL/6 wild-type mice had inferior vena cava VT induced by nonstasis or stasis mechanisms. In both models, VT size was largest at day 1 and trended down by day 21, and CCR7(+) cells peaked at day 8 in wild-type mice. No significant differences in VT resolution were found in CCR7(-/-) as compared with wild type in either model. In the nonstasis VT model, vein wall changes consistent with fibrotic injury were evidenced by significant increases in collagen I, III, matrix metalloproteinase 2, and transforming growth factor-β gene expression, increases in α-smooth muscle actin and fibroblast specific protein-1 antigen, and total collagen at 8 days. Correspondingly, SM22α and fibroblast specific protein-1, but not DDR2(+) cells, were increased at 8 days. Early wild-type thrombus exposure inhibited profibrotic gene expression in CCR7(-/-) in ex vivo vein wall culture. Bone marrow chimera experiments further showed that circulating CCR7(+) leukocytes partially rescued midterm profibrotic changes in CCR7(-/-) mice. In human histological sections of chronic thrombosed femoral veins, CCR7(+) cells were present in the fibrotic areas. CONCLUSIONS: Post-thrombotic vein wall remodeling is impaired in CCR7(-/-) mice, with a profibrotic phenotype, is dependent on the thrombotic mechanism, and is mediated by circulating CCR7(+) cells. Unlike other postinjury fibrotic responses, CCR7(+) signaling may be important for positive vein wall remodeling after VT.
Authors: Kristopher B Deatrick; Catherine E Luke; Megan A Elfline; Vikram Sood; Joseph Baldwin; Gilbert R Upchurch; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke Journal: J Vasc Surg Date: 2013-03-13 Impact factor: 4.268
Authors: P Prandoni; A W Lensing; A Cogo; S Cuppini; S Villalta; M Carta; A M Cattelan; P Polistena; E Bernardi; M H Prins Journal: Ann Intern Med Date: 1996-07-01 Impact factor: 25.391
Authors: Peter K Henke; Andrea Varga; Sumit De; C Barry Deatrick; Jonathon Eliason; Douglas A Arenberg; Pasu Sukheepod; Porama Thanaporn; Steven L Kunkel; Gilbert R Upchurch; Thomas W Wakefield Journal: Arterioscler Thromb Vasc Biol Date: 2004-04-22 Impact factor: 8.311
Authors: Nicholas A Dewyer; Osama M El-Sayed; Catherine E Luke; Megan Elfline; Nicolai Kittan; Ron Allen; Adriana Laser; Carson Oostra; Anthony Comerota; Cory Hogaboam; Steven L Kunkel; Peter K Henke Journal: Thromb Haemost Date: 2015-07-16 Impact factor: 5.249
Authors: Osama M El-Sayed; Nicholas A Dewyer; Catherine E Luke; Megan Elfline; Adriana Laser; Cory Hogaboam; Steven L Kunkel; Peter K Henke Journal: J Vasc Surg Date: 2015-10-23 Impact factor: 4.268
Authors: A T Obi; J A Diaz; N L Ballard-Lipka; K J Roelofs; D M Farris; D A Lawrence; T W Wakefield; P K Henke Journal: J Thromb Haemost Date: 2014-07-23 Impact factor: 5.824
Authors: Andrew Scott Kimball; Andrea Tara Obi; Catherine E Luke; Abigail R Dowling; Qing Cai; Reheman Adili; Hannah Jankowski; Matthew Schaller; Michael Holinstadt; Farouc A Jaffer; Steven L Kunkel; Katherine A Gallagher; Peter K Henke Journal: Thromb Haemost Date: 2019-12-30 Impact factor: 5.249
Authors: Marion Pilard; Estelle L Ollivier; Virginie Gourdou-Latyszenok; Francis Couturaud; Catherine A Lemarié Journal: Front Cardiovasc Med Date: 2022-04-21
Authors: Scott M Damrauer; Pradeep Natarajan; Derek Klarin; Emma Busenkell; Renae Judy; Julie Lynch; Michael Levin; Jeffery Haessler; Krishna Aragam; Mark Chaffin; Mary Haas; Sara Lindström; Themistocles L Assimes; Jie Huang; Kyung Min Lee; Qing Shao; Jennifer E Huffman; Christopher Kabrhel; Yunfeng Huang; Yan V Sun; Marijana Vujkovic; Danish Saleheen; Donald R Miller; Peter Reaven; Scott DuVall; William E Boden; Saiju Pyarajan; Alex P Reiner; David-Alexandre Trégouët; Peter Henke; Charles Kooperberg; J Michael Gaziano; John Concato; Daniel J Rader; Kelly Cho; Kyong-Mi Chang; Peter W F Wilson; Nicholas L Smith; Christopher J O'Donnell; Philip S Tsao; Sekar Kathiresan; Andrea Obi Journal: Nat Genet Date: 2019-11-01 Impact factor: 38.330